xM (NeXT Personal® Dx)
Use
xM (NeXT Personal® Dx) is a sophisticated whole genome assay designed for the early detection and monitoring of minimal residual disease (MRD) and recurrence in solid tumors, particularly in colorectal cancer. It is ultra-sensitive, capable of detecting ctDNA at concentrations as low as 1.67 PPM, allowing for the identification of up to 1800 somatic variants. The test aids in detecting molecular markers indicative of recurrent malignancy, even before they become apparent on radiographic scans. It is useful in monitoring the effectiveness of immune-oncology (IO) treatments across a range of cancer types, providing an essential tool for patient-tailored treatment strategies.
Special Instructions
xM is available for ordering with single or longitudinal MRD testing options, providing flexibility in monitoring schedules according to medical necessity. Tempus offers mobile phlebotomy services, making it convenient for patients unable to visit clinical settings. Ordering and results can be managed through the Tempus Hub online platform, with options for paper requisition and EHR integration. Financial assistance is available for eligible patients, with self-pay options for uninsured and international individuals.
Limitations
The test results could be limited by factors such as CHIP and germline variants, which are mitigated by a tumor normal matched approach. However, the ultra-sensitive nature of the assay means that it has a potential for false positives if not interpreted correctly within the clinical context. The efficacy and accuracy may vary dependent on the tumor type and size, and it may not detect ctDNA in all cases of recurrence or progression.
Methodology
NGS (WGS)
Biomarkers
Result Turnaround Time
4 weeks
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
3.3 ml
Container
EDTA Tube